Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
1995-05-31
2002-05-07
Gambel, Phillip (Department: 1644)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C435S002000, C530S387100, C530S387300, C530S388100, C530S388200, C530S388220, C530S388700, C530S388730, C530S388750
Reexamination Certificate
active
06384198
ABSTRACT:
BACKGROUND OF THE INVENTION
This invention is directed to monoclonal antibodies and Fv specifically binding CD2 antigen and the use of such monoclonal antibodies in preventing the production of the human immunodeficiency virus (HIV-1) in HIV-1-infected T cells.
Acquired immunodeficiency syndrome (AIDS) has become one of the most feared diseases of the latter part of the twentieth century. In the United States alone, about 40,000 new cases of AIDS are diagnosed yearly and at least 200,000 cases have occurred since the disease became recognized about 1981. It is believed that from 1 million to 1.5 million Americans are infected with HIV-1, which means that they are at risk to develop AIDS and are likely to do so unless a means can be found for preventing the development of the full-blown illness in patients infected with the virus. Worldwide, the number of cases of AIDS runs into the millions, with certain areas of Africa and the Caribbean having the highest rates of infection.
Until now, although the amount of money spent for research on AIDS equals or exceeds that spent for research on diseases such as cancer and heart disease, no cure is yet available and the disease is considered uniformly fatal. Although several treatments have been developed that appear to slow the progression of the disease, at least in some patients, such as the drugs azidothymidine (AZT) and dideoxyinosine (DDI), these treatments are regarded only as palliatives. They do not work in all patients, and their effectiveness tends to decrease over the course of the disease. Thus, additionally treatments for AIDS are urgently needed.
It is generally believed that infection with the human immunodeficiency virus (HIC-1) is required for development of AIDS, although other factors may contribute to the establishment and the progress of the disease, because the disease is often associated with drug abuse and with exposure to other pathogens that may contribute to or enhance the immunosuppressive effects. HIV-1 is a retrovirus of the lentivirus subfamily. Like other retroviruses, its life cycle involves reverse transcription and incorporation of the viral RNA genome as DNA into the genome of the infected T cell. Activation of the virus results in transcription and translation, leading to production of the virus and depletion of CD4
+
T cells.
One of the characteristics of AIDS is the presence of opportunistic infections. These infections include diarrhea caused by several bacterial species, tuberculosis caused by avian and bovine mycobacteria, viral infections such as cytomegalovirus infection and shingles caused by herpesvirus, fungal infections such as candidiasis, aspergillosis, and histoplasmosis, and protozoan infections such as toxoplasmosis and pneumocystis pneumonia. These infections are frequently the actual cause of death in patients with AIDS, and case much morbidity even when not fatal. Although treatments exist for a number of these opportunistic infections, such as aerosolized pentamidine for pneumocystis pneumonia, these treatments are often unsuccessful because of the general health of the patients and their decreased resistance to infection brought about by AIDS itself.
Thus, improved methods of treating such infections are required.
Like other lentiviruses, HIV-1 can remain latent within the DNA of infected CD4
+
T lymphocytes, often for long periods. This latency is poorly understood, but is likely dependent on the state of activation of the host CD4
+
T cell (Z. F. Rosenberg & A. F. Fauci, “Minireview: Induction of Expression of HIV in Latently or Chronically Infected Cells,”
AIDS Res. Hum. Retro,
5: 1-4 (1989)).
Activation of T cells is dependent on a complex scheme of interactions between them and other cells designated as antigen presenting cells (ACs). These interactions are mediated by specific binding between molecules on the cell surface of T cells and molecules on the surfaces of APCs. One such interaction is between CS2 on the surface of T cells and its ligand LFA-3 on APC. The CD2 molecule, when crosslinked by anti-CD2 antibodies, is capable of directly activating T cells. The LFA-3 ligand is also referred to as a counter-receptor. Other receptor/counter-receptor pairs are ICAM-1/CD18 and CS28/B7.
One of the paradoxes that has complicated both the effort to understand AIDS and the effort to treat the opportunistic infections associated with it is that attempts by HIV-1-infected lymphocytes to respond to organisms responsible for opportunistic infections results in increased production of HIV-1 virus by infected cells. This is shown by results indicating that response to staphylococcal enterotoxin (“superantigen” or “SAg”) increases HIV-1 production from infected cells in vitro.
Much remains to be understood about activation of HIV-1 production in infected lymphocytes. Various stimuli that have been shown to induce HIV-1 production by infected T-cell lines include the following: (1) T-cell antigens; (2) mitogens; (3) various cytokines such as TNF&agr;, IL-1, and IL-6; and (4) other viruses (Rosenberg and Fauci (1989), supra; Z. F. Rosenberg & A. F. Fauci, “Activation of Latent HIV Infection,”
J. NIH Res.
2:41-45 (1990)).
However, relatively little is known about mechanisms that activate HIV-1 expression in CD4
+
T cells that contain integrated HIV-1 provirus.
Accordingly, there is a need for a method of suppression or blocking of HIV-1 production without markedly altering immunological functions and immune response to pathogens other than HIV-1, or, if some response is suppressed in order to prevent HIV-1 production, to do so without depressing the clinical status of the patient. Such a method would be useful in treating opportunistic infections and in extending the life of patients infected with HIV-1.
SUMMARY
We have developed a chimeric humanized single-chain recombinant antibody, CD2 SFv-Ig, specifically binding to CD2 antigen, that can be used to suppress HIV-1 virus production in HIV-1-infected T cells, as well as other antibodies specifically binding CD2 antigen. We have also developed methods for suppressing virus production and treating subjects infected with HIV-1 using CD2 SFv-Ig or other antibodies specifically binding antigens involved in the intercellular interaction between T lymphocytes and monocytes.
Antibodies according to the present invention includes a single-chain recombinant antibody selected from the group consisting of:
(1) chimeric single-chain recombinant antibody CD2 SFv-Ig produced by expression of the construct cloned in recombinant
Escherichia coli
culture ATCC No. 69277;
(2) a antibody having complementarity-determining regions identical with those of CD2 SFv-Ig; and
(3) a antibody competing with CD2 SFv-Ig for binding to CD2 antigen at least about 80% as effectively on a molar basis as CD2 SFv-Ig.
Preferably, the antibody completes at least about 90% as effectively on a molar basis as CD2 SFv-Ig for binding to CD2 antigen.
The complementarity-determining regions of either H chain origin or L chain origin can be identical in sequence to those of cD2 SFv-Ig.
Preferably, the antibody is chimeric single-chain recombinant antibody CD2 SFv-Ig.
Another aspect of the invention is an antibody modified from the antibody described above by deletion of at least a portion of the Ig-derived amino acid sequence therefrom. The entire Ig-derived amino acid sequence can be deleted. Such an antibody can be derived from CD2 SFv-Ig.
The antibody can be labeled with a detectable marker. The detectable marker can be selected from the group consisting of enzymes, paramagnetic materials, members of the avidin-biotin specific binding pair, fluorophores, chromophores, chemiluminophores, heavy metals, and radioisotopes.
Alternatively, the antibody can be conjugated to a therapeutic agent. The therapeutic agent can be selected from the group consisting of antinenoplastic agents, lymphokines, and toxins. Suitable lymphokines include interleukins, interferons, and tumor necrosis factors, in particular, interleukin-2. Suitable toxins include ricin, pseudo
Diegel Michael L
Gilliland Lisa K
Ledbetter Jeffrey A
Linsley Peter S
Moran Patricia A
Bristol-Myers Sqibb Company
Gambel Phillip
Klein Christopher A.
Lange Keith R.
LandOfFree
Methods for inhibiting the production of HIV-1 retrovirus... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for inhibiting the production of HIV-1 retrovirus..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for inhibiting the production of HIV-1 retrovirus... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2905326